Navigation Links
Counterfeit antimalarial drug discovered in Ghana
Date:7/22/2009

Rockville, Md., July 22, 2009 Quantities of a prescription medication used throughout the world for treating malaria have been identified as lacking any active ingredient and presumably counterfeit. These are being removed from the market in Ghana, where they were discovered recently and confirmed as fake last Friday. The discovery was made by a vigilant citizen who contacted the Medicines Quality Monitoring program set up by the U.S. Agency for International Development (USAID)-supported Drug Quality and Information (DQI) Program, implemented by the U.S. Pharmacopeial (USP) Convention. USP is a nonprofit scientific organization that develops globally recognized standards for the quality of medicines. Through the DQI Program, USP works in developing countries to help verify, assure and improve the quality of medicines intended to treat life-threatening neglected diseases such as malaria, HIV/AIDS and tuberculosis, as well as advance the appropriate use of these medicines.

The fake drug found in Ghana did not contain the active pharmaceutical ingredients of the Novartis Coartem product it was being sold as, posing a significant health threat to patients relying on the medication. This drug is an artemisinin-based combination therapy recommended by the World Health Organization (WHO) for treating "uncomplicated" malaria, which is endemic in 108 countries, 45 in Africa. A major barrier in combating malaria throughout much of the developing world is the widespread presence of counterfeit and adulterated drugs, which undermines the public health. Not only do these drugs fail to deliver the appropriate treatment to individual patientsputting their lives at riskbut they contribute to the growth of drug-resistant strains of malaria, one of the greatest challenges to malaria control today.

In this case, a local citizen brought a suspicious sample of "Coartem" to one of five sentinel sites set up in the country to monitor and test medicine quality. Aft
'/>"/>

Contact: Francine Pierson
fp@usp.org
301-816-8588
US Pharmacopeia
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. IntegriChain Enlists Ed Casey and Associates to Drive Counterfeit and Diversion Monitoring Service
2. Warning - Beware of Counterfeit Coda(R) Products
3. U.S. on Sidelines as Nations Launch Negotiations on Treaty to Combat Smuggling, Counterfeiting and Other Illicit Trade in Tobacco Products
4. Indiana Adopts Legislation to Combat Illegitimate Online Pharmacies, Protect Residents From Counterfeit Drugs
5. Partnership for Safe Medicines Arms Public Against Counterfeit Drugs
6. USP announces new standards to protect patients from counterfeit and adulterated medicines
7. UL Warns of Counterfeit Electric Signs
8. New Momentum Launches Anti-Counterfeiting Software for Pharmaceutical Companies
9. IBM and Golden State Medical Supply Create Drug Safety Model to Help Combat Counterfeiting
10. Appropriate medical screening for antimalarials vital to US military personnel
11. WRAIR investigators pioneering work on an exciting new class of antimalarial compounds
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 2Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 3Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 4Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 5Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 2Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 3Health News:U.S. Cancer Cases, Deaths Continue to Drop 2Health News:U.S. Cancer Cases, Deaths Continue to Drop 3Health News:U.S. Cancer Cases, Deaths Continue to Drop 4Health News:Docs Not Giving Clear Advice on Infant Sleep Positions 2Health News:Docs Not Giving Clear Advice on Infant Sleep Positions 3Health News:The Dignity Memorial(R) Network Honors Four Individuals Who Gave the Gift of Life Through Organ and Tissue Donation 2Health News:The Dignity Memorial(R) Network Honors Four Individuals Who Gave the Gift of Life Through Organ and Tissue Donation 3
Breaking Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3IEEE USA President endorses national innovation strategy 10050 1Utah ethicist heads stem cell panel 10048 1Utah ethicist heads stem cell panel 10048 2Utah ethicist heads stem cell panel 10048 3New beryllium reference material for occupational safety monitoring 10046 1New beryllium reference material for occupational safety monitoring 10046 2